

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

DMS

Display Date 6-2-03  
Publication Date 6-3-03  
Signature G. Trenley

Arthritis Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

---

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Arthritis Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on June 23 and 24, 2003, from 8 a.m. to 5 p.m.

*Location:* Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

*Contact Person:* Johanna Clifford, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: cliffordj@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12532. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On June 23, 2003, the committee will discuss fibromyalgia, clinical trial design, including important disease endpoints in the study, and

development of therapies and treatments. On June 24, 2003, the committee will discuss the safety and efficacy of submission tracking number 103795/5123, ENBREL (etanercept), Immunex, for reducing signs and symptoms of active ankylosing spondylitis.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 13, 2003. Oral presentations from the public will be scheduled between approximately 11:30 a.m. and 12 noon on both days. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 13, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact LaNise Giles at 301-827-7001, at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act

(5 U.S.C. app. 2).

Dated: 5/24/03  
May 24, 2003.

  
\_\_\_\_\_  
Peter J. Pitts,  
Associate Commissioner for External Relations.

[FR Doc. 03-????? Filed ??-??-03; 8:45 am]

**BILLING CODE 4160-01-S**

CERTIFIED TO BE A  
COPY OF THE ORIGINAL  
